The idea of using PTP1B inhibitor as an anti-cancer treatment was first suggested by observing that a specific PTP1B inhibitor significantly delayed the development of breast tumor in NDL2 transgenic mice via attenuating the MAPK and Akt pathways38. The gene discussed is PTPN1; the disease is cancer.